Price T Rowe Associates Inc. MD Has $3.39 Billion Position in argenx SE (NASDAQ:ARGX)

Price T Rowe Associates Inc. MD lessened its stake in argenx SE (NASDAQ:ARGX - Free Report) by 5.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,516,894 shares of the company's stock after selling 303,653 shares during the quarter. Price T Rowe Associates Inc. MD owned about 9.08% of argenx worth $3,392,891,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the stock. GeoWealth Management LLC grew its position in shares of argenx by 56.3% during the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company's stock worth $31,000 after buying an additional 18 shares during the period. Steward Partners Investment Advisory LLC lifted its stake in shares of argenx by 5.6% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company's stock valued at $234,000 after purchasing an additional 20 shares during the period. SG Americas Securities LLC boosted its position in shares of argenx by 6.2% in the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company's stock worth $220,000 after purchasing an additional 21 shares during the last quarter. Farther Finance Advisors LLC grew its stake in shares of argenx by 38.2% during the fourth quarter. Farther Finance Advisors LLC now owns 76 shares of the company's stock worth $47,000 after purchasing an additional 21 shares during the period. Finally, Dynasty Wealth Management LLC increased its holdings in argenx by 3.4% in the fourth quarter. Dynasty Wealth Management LLC now owns 677 shares of the company's stock valued at $416,000 after purchasing an additional 22 shares during the last quarter. 60.32% of the stock is owned by institutional investors.

argenx Stock Up 0.1 %

Shares of NASDAQ:ARGX traded up $0.69 during midday trading on Monday, hitting $615.45. The stock had a trading volume of 116,511 shares, compared to its average volume of 307,372. The business's 50-day simple moving average is $598.28 and its 200-day simple moving average is $609.01. argenx SE has a 12 month low of $352.77 and a 12 month high of $678.21. The company has a market cap of $37.58 billion, a P/E ratio of -698.76 and a beta of 0.60.

argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.60. The company had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. As a group, equities analysts predict that argenx SE will post 3.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. HC Wainwright reaffirmed a "buy" rating and issued a $720.00 price target on shares of argenx in a research note on Tuesday, April 8th. Sanford C. Bernstein upgraded shares of argenx from a "market perform" rating to an "outperform" rating in a research report on Monday, March 17th. Robert W. Baird lifted their target price on argenx from $650.00 to $680.00 and gave the stock a "neutral" rating in a report on Tuesday, March 4th. JMP Securities increased their price target on argenx from $606.00 to $696.00 and gave the stock a "market outperform" rating in a report on Tuesday, January 14th. Finally, Citigroup lifted their price objective on argenx from $681.00 to $796.00 and gave the company a "buy" rating in a report on Thursday, April 17th. Three analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, argenx currently has a consensus rating of "Moderate Buy" and a consensus price target of $699.28.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.